-
1دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
2دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
3دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
4دورية أكاديمية
المؤلفون: Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, Derosa SC, Defawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL
المصدر: Journal of Infectious Diseases; Mar2011, Vol. 203 Issue 5, p610-619, 10p
مصطلحات موضوعية: HIV prevention, VACCINES, VIRUSES, AIDS vaccines, DRUG administration, PLACEBOS, CD4 lymphocyte count, BLIND experiment, ENZYME-linked immunosorbent assay, GENES, RESEARCH funding, T cells, VIRAL antibodies, HIV
مصطلحات جغرافية: UNITED States
-
5دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
6دورية أكاديمية
المؤلفون: Cohen KW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Fiore-Gartland A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Walsh SR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Yusim K; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, and New Mexico Consortium, Los Alamos, New Mexico, USA., Frahm N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Global Health, University of Washington, Seattle, Washington, USA., Elizaga ML; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Maenza J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Scott H; San Francisco Department of Public Health, San Francisco, California, USA., Mayer KH; Harvard Medical School, Boston, Massachusetts, USA.; The Fenway Institute, Fenway Health, Boston, Massachusetts, USA., Goepfert PA; University of Alabama at Birmingham, Birmingham, Alabama, USA., Edupuganti S; Emory University, Atlanta, Georgia, USA., Pantaleo G; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., Hutter J; Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA., Morris DE; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., De Rosa SC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Geraghty DE; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Robb ML; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA., Michael NL; Walter Reed Army Institute of Research, Silver Spring, Maryland, USA., Fischer W; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, and New Mexico Consortium, Los Alamos, New Mexico, USA., Giorgi EE; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, and New Mexico Consortium, Los Alamos, New Mexico, USA., Malhi H; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Pensiero MN; Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA., Ferrari G; Duke Human Vaccine Institute and.; Department of Surgery, Duke University, Durham, North Carolina, USA., Tomaras GD; Duke Human Vaccine Institute and.; Department of Surgery, Duke University, Durham, North Carolina, USA., Montefiori DC; Duke Human Vaccine Institute and.; Department of Surgery, Duke University, Durham, North Carolina, USA., Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Haynes BF; Duke Human Vaccine Institute and., Korber BT; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, and New Mexico Consortium, Los Alamos, New Mexico, USA., Baden LR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.
مؤلفون مشاركون: NIAID HVTN 106 Study Group
المصدر: The Journal of clinical investigation [J Clin Invest] 2023 Feb 15; Vol. 133 (4). Date of Electronic Publication: 2023 Feb 15.
نوع المنشور: Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
مواضيع طبية MeSH: HIV Infections* , AIDS Vaccines* , Vaccines, DNA*, Animals ; Consensus ; Immunity, Cellular ; Vaccination ; Vaccinia virus ; HIV Antibodies
-
7دورية أكاديمية
المؤلفون: Spearman P; Department of Pediatrics, Cincinnati Children's Hospital, Ohio., Tomaras GD; Department of Surgery, Duke University Medical Center, Durham, North Carolina., Montefiori DC; Department of Surgery, Duke University Medical Center, Durham, North Carolina., Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Elizaga ML; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Ferrari G; Department of Surgery, Duke University Medical Center, Durham, North Carolina., Alam SM; Department of Surgery, Duke University Medical Center, Durham, North Carolina., Isaacs A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Ahmed H; Department of Biology, Emory University, Atlanta, Georgia., Hural J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Ouedraogo L; Division of AIDS, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland., Pensiero M; Division of AIDS, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland., Butler C; Division of AIDS, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland., Kalams SA; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee., Overton ET; Department of Medicine, University of Alabama at Birmingham, Cambridge, Massachusetts., Barnett SW; Novartis Vaccines, Cambridge, Massachusetts.
المصدر: The Journal of infectious diseases [J Infect Dis] 2019 May 05; Vol. 219 (11), pp. 1755-1765.
نوع المنشور: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE
مواضيع طبية MeSH: HIV Antibodies/*immunology , HIV Infections/*prevention & control , HIV-1/*immunology, Adjuvants, Immunologic ; Adolescent ; Adult ; Antibodies, Neutralizing/immunology ; HIV Infections/virology ; Humans ; Immunization, Secondary ; Middle Aged ; Vaccination ; Young Adult
-
8دورية أكاديمية
المؤلفون: Elizaga ML; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Li SS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Kochar NK; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Wilson GJ; Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America., Allen MA; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America., Tieu HVN; Laboratory of Infectious Disease Prevention, New York Blood Center, New York, New York, United States of America., Frank I; Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America., Sobieszczyk ME; Division of Infectious Diseases, Columbia University Medical Center, New York, New York, United States of America., Cohen KW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Sanchez B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Latham TE; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America., Clarke DK; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America., Egan MA; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America., Eldridge JH; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America., Hannaman D; Ichor Medical Systems, Incorporated, San Diego, California, United States of America., Xu R; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America., Ota-Setlik A; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.; Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America.; Department of Global Health, University of Washington, Seattle, Washington, United States of America.; Department of Medicine, University of Washington, Seattle, Washington, United States of America., Hay CM; Infectious Diseases Division, University of Rochester Medical Center, Rochester, New York, United States of America.
مؤلفون مشاركون: NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team
المصدر: PloS one [PLoS One] 2018 Sep 20; Vol. 13 (9), pp. e0202753. Date of Electronic Publication: 2018 Sep 20 (Print Publication: 2018).
نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
مواضيع طبية MeSH: AIDS Vaccines/*administration & dosage , Genetic Vectors/*administration & dosage , Interleukin-12/*genetics , Vaccines, Attenuated/*administration & dosage , Vaccines, DNA/*administration & dosage , Vesicular stomatitis Indiana virus/*genetics, AIDS Vaccines/adverse effects ; Adult ; Combined Modality Therapy ; Double-Blind Method ; Electroporation ; Female ; Genetic Vectors/adverse effects ; HIV-1 ; Healthy Volunteers ; Humans ; Immunization, Secondary ; Injections, Intramuscular ; Male ; Middle Aged ; Plasmids/genetics ; Vaccines, Attenuated/adverse effects ; Vaccines, DNA/adverse effects ; Young Adult ; gag Gene Products, Human Immunodeficiency Virus
-
9دورية أكاديمية
المؤلفون: Gray GE; Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa Glenda.gray@mrc.ac.za.; South African Medical Research Council, Cape Town, South Africa., Mayer KH; Fenway Health and Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Elizaga ML; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Bekker LG; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Allen M; DAIDS, NIAID, NIH, Washington, DC, USA., Morris L; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa., Montefiori D; Duke University, Durham, North Carolina, USA., De Rosa SC; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Sato A; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Gu N; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Tomaras GD; Duke University, Durham, North Carolina, USA., Tucker T; South African Medical Research Council, Cape Town, South Africa., Barnett SW; Novartis Vaccines, Cambridge, Massachusetts, USA., Mkhize NN; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa., Shen X; Duke University, Durham, North Carolina, USA., Downing K; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Williamson C; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.; National Health Laboratory Service, Cape Town, South Africa., Pensiero M; DAIDS, NIAID, NIH, Washington, DC, USA., Corey L; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Williamson AL; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.; National Health Laboratory Service, Cape Town, South Africa.
المصدر: Clinical and vaccine immunology : CVI [Clin Vaccine Immunol] 2016 Jun 06; Vol. 23 (6), pp. 496-506. Date of Electronic Publication: 2016 Jun 06 (Print Publication: 2016).
نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
بيانات الدورية: Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 101252125 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1556-679X (Electronic) Linking ISSN: 1556679X NLM ISO Abbreviation: Clin Vaccine Immunol Subsets: MEDLINE
مواضيع طبية MeSH: Immunization Schedule* , Immunization, Secondary*/adverse effects, AIDS Vaccines/*immunology , Acquired Immunodeficiency Syndrome/*prevention & control , Antibodies, Neutralizing/*blood , Vaccines, DNA/*immunology , env Gene Products, Human Immunodeficiency Virus/*immunology, AIDS Vaccines/administration & dosage ; AIDS Vaccines/classification ; Adolescent ; Adult ; CD4 Lymphocyte Count ; Enzyme-Linked Immunospot Assay ; Female ; HIV Antibodies/blood ; HIV Antibodies/immunology ; HIV-1/immunology ; Humans ; Immunity, Cellular ; Injections, Intramuscular ; Male ; South Africa ; Time Factors ; Vaccination ; Vaccines, DNA/administration & dosage ; Vaccinia/genetics ; Vaccinia/immunology ; Young Adult ; env Gene Products, Human Immunodeficiency Virus/administration & dosage
-
10دورية أكاديمية
المؤلفون: Fuchs JD; San Francisco Department of Public Health, California ; University of California , San Francisco., Frank I; University of Pennsylvania , Philadelphia., Elizaga ML; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center., Allen M; Division of AIDS, National Institutes of Allergy and Infectious Diseases , Bethesda, Maryland., Frahm N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center., Kochar N; Statistical Center for HIV/AIDS Research and Prevention , Fred Hutchinson Cancer Research Center , Seattle, Washington., Li S; Statistical Center for HIV/AIDS Research and Prevention , Fred Hutchinson Cancer Research Center , Seattle, Washington., Edupuganti S; Emory University , Atlanta, Georgia., Kalams SA; Vanderbilt University , Nashville, Tennessee., Tomaras GD; Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina., Sheets R; Division of AIDS, National Institutes of Allergy and Infectious Diseases , Bethesda, Maryland., Pensiero M; Division of AIDS, National Institutes of Allergy and Infectious Diseases , Bethesda, Maryland., Tremblay MA; Profectus Biosciences, Inc. , Tarrytown, New York., Higgins TJ; Profectus Biosciences, Inc. , Tarrytown, New York., Latham T; Profectus Biosciences, Inc. , Tarrytown, New York., Egan MA; Profectus Biosciences, Inc. , Tarrytown, New York., Clarke DK; Profectus Biosciences, Inc. , Tarrytown, New York., Eldridge JH; Profectus Biosciences, Inc. , Tarrytown, New York., Mulligan M, Rouphael N, Estep S, Rybczyk K, Dunbar D, Buchbinder S, Wagner T, Isbell R, Chinnell V, Bae J, Escamilla G, Tseng J, Fair R, Ramirez S, Broder G, Briesemeister L, Ferrara A
مؤلفون مشاركون: HVTN 090 Study Group and the National Institutes of Allergy and Infectious Diseases HIV Vaccine Trials Network
المصدر: Open forum infectious diseases [Open Forum Infect Dis] 2015 Jun 05; Vol. 2 (3), pp. ofv082. Date of Electronic Publication: 2015 Jun 05 (Print Publication: 2015).
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Published by Oxford University Press on behalf of the Infectious Diseases Society of America Country of Publication: United States NLM ID: 101637045 Publication Model: eCollection Cited Medium: Print ISSN: 2328-8957 (Print) Linking ISSN: 23288957 NLM ISO Abbreviation: Open Forum Infect Dis Subsets: PubMed not MEDLINE